icd 9 code for procalcitonin

What are the new ICD 10 codes?

Procalcitonin - Used in the diagnosis of bacteremia and septicemia in adults and children (including neonates), renal involvement in urinary tract infection in children, bacterial infection in neutropenic patients, and in the diagnosis, risk stratification, and monitoring of septic shock, systemic secondary infection post-surgery, as well as in severe trauma, burns, and multiorgan …

Where can one find ICD 10 diagnosis codes?

Apr 06, 2022 · procalcitonin, serum a.k.a. Septic Shock, Sepsis, procalc, PCT. Test information includes: LOINC codes; diseases the test is often used to detect or monitor; ... diagnosis and billing codes ICD-10-CM; ICD-9-CM; CPT; additional or related tests; references - more information about the tests;

How many ICD 10 codes are there?

ICD-9-CM 790.6 is a billable medical code that can be used to indicate a diagnosis on a reimbursement claim, however, 790.6 should only be used for claims with a date of service on or before September 30, 2015. For claims with a date of service on or after October 1, 2015, use an equivalent ICD-10-CM code (or codes).

What are ICD-10 diagnostic codes?

CPT codes covered if selection criteria are met: 84145: Procalcitonin (PCT) Other CPT codes related to the CPB: 33016 – 33997: Surgery; Heart and pericardium : 35301: Thromboendarterectomy, including patch graft, if performed; carotid, vertebral, subclavian, by neck incision: ICD-10 codes covered if selection criteria are met: J00 - J06.9

What is procalcitonin?

Procalcitonin (PCT), a protein that consists of 116 amino acids, is the peptide precursor of calcitonin, a hormone that is synthesized by the parafollicular C cells of the thyroid and involved in calcium homeostasis. Procalcitonin arises from endopeptidase-cleaved preprocalcitonin.Oct 22, 2021

What is the CPT code for procalcitonin?

84145Test Name:PROCALCITONINAlias:LAB9757 PCTCPT Code(s):84145Preferred Specimen:1.0 mL plasmaContainer:Lithium Heparin (lt green)16 more rows

What is procalcitonin blood test used for?

A procalcitonin test is a type of blood test used to detect sepsis . Sepsis is a potentially deadly condition in which the body overreacts to a bacterial infection by releasing chemicals that can cause damaging inflammation. If left untreated, sepsis can become severe enough to cause organ failure and death.Nov 11, 2021

What top is procalcitonin?

PROCALCITONINORDERING INFORMATION:Geisinger Epic Procedure Code: LAB2920 Geisinger Epic ID: 48115Specimen type:Plasma (preferred) or serumPreferred collection container:3 mL green/yellow-top (plasma separator) tubeAlternate Collection Container:3.5 mL gold-top (serum separator) tube20 more rows•Jan 4, 2022

What is a procalcitonin level?

What is a procalcitonin test? A procalcitonin test measures the level of procalcitonin in your blood. A high level could be a sign of a serious bacterial infection, such as sepsis. Sepsis is the body's severe response to infection.Nov 30, 2020

How do you collect procalcitonin?

Collection Instructions Allow blood (red-top) to fully coagulate at room temperature. Within 1 hour of collection, centrifuge serum at 2000 rpm for 10 minutes.

What is difference between CRP and procalcitonin?

PCT can be used as a prognostic marker as its levels correlate with bacterial load and severity of infection, which is not the case for CRP. PCT has a plasma elimination half-life of 24–35 hours (vs 48 hours for CRP), which makes daily measurement of the levels clinically significant.

What does C stands for in PCT?

Background. Procalcitonin (PCT) is an inflammatory marker that has been used as indicator of severe bacterial infection. We evaluated the concentrations of PCT as a marker for systemic infection compared to C-reactive protein (CRP) in patients neutropenic febrile.

Why is procalcitonin elevated in infection?

Procalcitonin (PCT) is a peptide precursor of the hormone calcitonin. The level of PCT increases in response to a pro-inflammatory stimulus, especially of bacterial origin. The high PCT levels produced during infection are not followed by a parallel increase in calcitonin or serum calcium levels.

Is calcitonin the same as procalcitonin?

Procalcitonin is the precursor protein of the hormone Calcitonin. Both PCT and Calcitonin are distinct proteins. Calcitonin is exclusively produced by C-cells of the thyroid gland in response to hormonal stimuli.

What tube do you use for procalcitonin?

Specimen RequirementsSpecimen. Serum or plasma, frozen.Volume. 0.8 mL.Minimum Volume. 0.5 mL (Note: This volume does not allow for repeat testing.)Container. Red-top tube, gel-barrier tube, green-top (lithium heparin) tube, or lavender-top (EDTA) tube.Collection. ... Storage Instructions.

What is PCT in Aetna?

Aetna considers the measurement of procalcitonin ( PCT) medically necessary for initiating and discontinuing antibiotic therapy in persons in the intensive care unit and for persons with respiratory tract infections in the inpatient hospital setting to reduce antibiotic prescription rates and duration of use.

Where is PCT found?

Procalcitonin (PCT), a propeptide synthesized in the C cells of the thyroid, is a precursor of calcitonin. Procalcitonin is not found in the serum of healthy individuals; however, in response to bacterial infections, a rapid rise in serum PCT levels occurs.

Is PCT used for candidemia?

Cortegiani and colleagues (2019) the role of PCT in the differential diagnosis between bacteremia and candidemia is unclear. In a systematic review, these investigators evaluated the evidence on PCT values for differentiating bacteremia from candidemia. PubMed and Embase were searched for studies reporting data on the diagnostic performance of serum PCT levels in ICU or non-ICU adult patients with candidemia, in comparison to patients with bacteremia. These researchers included 16 studies for a total of 45,079 patients and 785 cases of candidemia. Most studies claimed to report data relating to the use of PCT values for differentiating between candidemia and bacteremia in septic patients in the ICU. However, the studies identified were all retrospective, except for 1 secondary analysis of a prospective data-set, and clinically very heterogeneous and involved different assessment methods. Most studies did show lower PCT values in patients with candidemia compared to bacteremia. However, the evidence supporting this observation was of low quality and the difference appeared insufficiently discriminative to guide therapeutic decisions. None of the studies retrieved actually studied guidance of anti-fungal treatment by PCT; PCT may improve diagnostic performance regarding candidemia when combined with other biomarkers of infection (e.g., beta-D-glucan); however, more data are needed. The authors concluded that PCT should not be used as a stand-alone tool for the differential diagnosis between bacteremia and candidemia due to limited supporting evidence. These researchers stated that PCT should be further examined in anti-fungal stewardship programs, in association with other biomarkers or non-culture diagnostic tests.

Is PCT a biomarker?

Dilger and colleagues (2019) described the existing literature on PCT as a biomarker in patients with acute rhino-sinusitis (ARS), analyzed outcomes in ARS patients who were treated with PCT-guided therapy versus traditional management, and compared PCT to other biomarkers used in diagnosis of bacterial ARS. These investigators carried out a search in the PubMed and Embase databases to identify studies related to PCT as a biomarker in ARS. After critical appraisal of validity by 2 authors, 6 studies with a total of 313 patients were selected for data extraction and analysis. They identified 2 randomized control trials (RCTs) of PCT-based guidelines for antibiotic management of ARS in out-patient settings and 4 observational studies that compared PCT to other biomarkers in patients with ARS. The 2 RCTs demonstrated a reduction (41.6 % in 1 study and 71 % in the other) in antibiotic prescription rate in the PCT-guided group versus the control group with no change in the number of days with impaired activity due to illness (9.0 versus 9.0 days [p = 0.96]; 8.1 versus 8.2 days [95 % CI: -0.7 to 0.7]), number of days of work missed, and percentage of patients with persistent symptoms at 28 days. In the observational cohort studies, PCT did not consistently correlate with CRP, body temperature, and/or WBC. The authors concluded that literature on PCT as a serum biomarker for diagnosis and appropriate antibiotic treatment of ARS is limited, and no studies have addressed the role of PCT in management of chronic rhino-sinusitis (CRS). Existing data on PCT-guided antibiotic treatment of acute lower respiratory tract infections (RTIs), including ARS, have shown non-inferior outcomes despite decreased antibiotic use; PCT does not consistently correlate with CRP; however, CRP is not currently used as a biomarker for ARS, thus this lack of correlation does not negate the role for PCT in management of ARS. These researchers stated that there is a need for further research, such as a large-scale RCT, to examine the potential utility of PCT-guided management of ARS.

Is IL-6 a biomarker for PJI?

Yoon and colleagues (2018) noted that many studies have found associations between laboratory biomarkers and peri-prosthetic joint infection (PJI), but it remains unclear whether these biomarkers are clinically useful in ruling out PJI. This meta-analysis compared the performance of IL-6 versus PCT for the diagnosis of PJI. In this meta-analysis, these investigators reviewed studies that evaluated IL-6 or/and PCT as a diagnostic biomarker for PJI and provided sufficient data to permit sensitivity and specificity analyses for each test. The major databases Medline, Embase, the Cochrane Library, Web of Science, and SCOPUS were searched for appropriate studies from the earliest available date of indexing through February 28, 2017. No restrictions were placed on language of publication. These researchers identified a total of 18 studies encompassing 1,835 subjects; 16 studies reported on IL-6 and 6 studies reported on PCT. The area under the curve (AUC) was 0.93 (95 % CI: 0.91 to 0.95) for IL-6 and 0.83 (95 % CI: 0.79 to 0.86) for PCT. The pooled sensitivity was 0.83 (95 % CI: 0.74 to 0.89) for IL-6 and 0.58 (95 % CI: 0.31 to 0.81) for PCT. The pooled specificity was 0.91 (95 % CI: 0.84 to 0.95) for IL-6 and 0.95 (95 % CI: 0.63 to 1.00) for PCT. Both the IL-6 and PCT tests had a high positive likelihood ratio (LR); 9.3 (95 % CI: 5.3 to 16.2) and 12.4 (95 % CI: 1.7 to 89.8), respectively, making them excellent rule-in tests for the diagnosis of PJI. The pooled negative LR for IL-6 was 0.19 (95 % CI: 0.12 to 0.29), making it suitable as a rule-out test, whereas the pooled negative LR for PCT was 0.44 (95 % CI: 0.25 to 0.78), making it unsuitable as a rule-out diagnostic tool. The authors concluded that based on the results of the present meta-analysis, IL-6 had higher diagnostic value than PCT for the diagnosis of PJI. Moreover, the specificity of the IL-6 test was higher than its sensitivity. Conversely, PCT is not recommended for use as a rule-out diagnostic tool.

Is PCT a prognostic biomarker?

In a systematic review and meta-analysis, Shin and colleagues (2019) examined the evidence on the usefulness of the PCT as a prognostic blood biomarker for outcomes in post-cardiac arrest patients. These investigators searched Medline, Embase, and the Cochrane Library (search date: January 8, 2019). Studies on patients who experienced return of spontaneous circulation, who had out-of-hospital cardiac arrest and had their level of PCT measured and outcomes assessed at and after hospital discharge, were included. In addition, these investigators performed subgroup analyses for confounding factors affecting patients' outcomes. To assess the risk of bias of each included study, the Quality in Prognosis Studies tool was used. A total of 1,065 patients from 10 studies were finally included. Elevated PCT level during hospital admission (at 0 to 24 hours) was associated with in-hospital mortality (standardized mean difference (SMD) 0.64, 95 % CI: 0.33 to 0.95, I2 = 26 %). The elevation of PCT level (at 0 to 48 hours) was also associated with poor neurologic outcomes (at 0 to 24 hours, SMD 0.61; 95 % CI: 0.44 to 0.79, I2 = 0 %; at 24 to 48 hours, SMD 0.58, 95 % CI: 0.35 to 0.82, I2 = 0 %) as well as at 1 to 6 months (at 24 to 48 hours, SMD 0.62; 95 % CI: 0.36 to 0.88, I2 = 0 %). The authors concluded that the findings suggested that an elevated PCT level measured at 0 to 48 hours of post-cardiac arrest syndrome was associated with poor outcomes. These findings need to be validated by well-designed studies.